Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2012 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

Components of
DTaP Vaccine
Excipients Table
Allergens Table
Components Table

Indication

To prevent infection with Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis

Proprietary Name

Daptacel

Infanrix

Kinrix

Tripedia

Manufacturer

sanofi pasteur

GlaxoSmithKline

GlaxoSmithKline

sanofi pasteur

Viability

Inactivated bacterial vaccine

Inactivated bacterial vaccine

Inactivated bacterial vaccine

Inactivated bacterial vaccine

Microorganism

Bordetella pertussis, Corynebacterium diphtheriae, Clostridium tetani

Bordetella pertussis, Corynebacterium diphtheriae, Clostridium tetani

Bordetella pertussis, Corynebacterium diphtheriae, Clostridium tetani

Bordetella pertussis, Corynebacterium diphtheriae, Clostridium tetani

Indicated Ages 6 weeks - <7 years 6 weeks - <7 years 4-6 years 6 weeks - <7 years

Dose

0.5 mL

0.5 mL

0.5 mL

0.5 mL

Route

Intramuscular

Intramuscular

Intramuscular

Intramuscular

Dose form

Suspension

Suspension

Suspension

Suspension

Appearance

White homogeneous cloudy suspension after shaking

Turbid white suspension after shaking

Homogeneous, turbid white suspension

Homogenous white suspension after shaking

Concentration (per 0.5  mL)

 

Diphtheria, 15 Lf

Tetanus, 5 Lf

PT, 10mcg

Filamentous hemagglutinin, 5 mcg

Pertactin, 3mcg

Fimbriae types 2 and 3, 5 mcg

Diphtheria, 25 Lf

Tetanus, 10 Lf

Pertussis, 25 mcg

Filamentous hemagglutinin, 25 mcg

Pertactin, 8 mcg 

Diphtheria, 25 Lf

Tetanus toxoid, 10 Lf

Pertussis toxin, 25 mcg

Filamentous hemagglutinin, 25 mcg

Pertactin, 8 mcg

Type 1 poliovirus, 40 DU

Type 3 poliovirus, 32 DU

Diphtheria, 6.7 Lf

Tetanus, 5 Lf

Pertussis toxin (PT), 23.4 mcg

Filamentous Hemaglutinin (FHA), 23 mcg

Preservatives/dose

2-Phenoxyethanol, 3.3 mg (0.6% v/v)

None

None

Thimerosal, ≤0.3 mcg

Adjuvant

Aluminum Phosphate, 0.33 mg

Aluminum Hydroxide, ≤0.625 mg

Aluminum Hydroxide, ≤0.6 mg

Aluminum potassium sulfate, ≤0.17 mg

Excipients

Formaldehyde, ≤0.1 mg

Glutaraldehyde, ≤50 ng

Formaldehyde, ≤100 mcg

Polysorbate 80, ≤ 100 mcg

Sodium chloride, 4.5 mg/mL

Formaldehyde, ≤100 mcg

Polysorbate 80, ≤ 100 mcg

Sodium chloride, 4.5 mg

Formaldehyde, ≤100 mcg

Gelatin

Polysorbate 80

Allergens

Stopper vial may contain dry natural latex rubber

One type prefilled syringe has a tip cap which may contain natural rubber latex and a plunger which does not contain latex.

The other type has a tip cap and a rubber plunger which contain dry natural latex rubber.

The vial stopper does not contain latex.

Neomycin, ≤0.05 ng

Polymyxin B, ≤0.01 ng

One type prefilled syringe has a tip cap which may contain natural rubber latex and a plunger which does not contain latex.

The other type has a tip cap and a rubber plunger which contain dry natural latex rubber.

The vial stopper does not contain latex.

Stopper vial may contain dry natural latex rubber

Media

       

Bordetella pertussis

Stainer-Scholte medium

Modified by Casamino Acids and Dimethyl-beta-cyclodextrin

Modified Stainer-Scholte liquid medium

Modified Stainer-Scholte liquid medium

Stainer-Scholte modified by casamino acids and dimethyl-beta-cyclodextrin

Corynebacterium diphtheria

Modified Mueller’s growth medium

Purified using  Ammonium Sulfate Fractionation.

Detoxified using Formalin

Fenton medium containing bovine extract

Detoxified using Formaldehyde

PT detoxified using Glutaraldehyde

FHA and Pertactin detoxified using formaldehyde

Fenton medium containing bovine extract

Modified Mueller’s growth medium

Detoxified using formaldehyde

Purified using serial ammonium sulfate fractionation and diafiltration

Clostridium tetani

Mueller-Miller Casamino acid medium

Detoxified using formalin

Purified by Ammonium Sulfate fractionation

Modified Lantham medium derived from bovine casein

Detoxified using formaldehyde

Modified Lantham medium derived from bovine casein

Peptone-based medium containing a bovine extract

Detoxified using formaldehyde

Purified using serial ammonium sulfate fractionation and diafiltration

Packaging

0.5 mL vials

0.5 mL vials and disposable prefilled syringes

0.5 mL vials and disposable prefilled syringes

0.5 mL vials

Routine Storage

2 to 8° C (35-46° F)

Do not freeze

2 to 8° C (36-46° F)

Do not freeze

2 to 8° C (36-46° F)

Do not freeze

2 to 8° C (35-46° F)

Do not freeze

PI Last Updated March 2003 August 2010 August 2010 December 2005

updated Nov 2010

 

 

This page was last updated on November 07, 2012

© 2010 Institute for Vaccine Safety